29 June 2022 · Three licensed ranibizumab biosimilars are available: Byooviz, Ongavia and Ximluci. Learn about the licensed indications and supporting evidence
29 June 2022 · Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
29 June 2022 · Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance
22 February 2023 · Understand the adalimumab products that are available on contract to the NHS. Choose between them appropriately for organisations or individuals.